Roswell Park, Generate Biomedicines launch exclusive clinical trial of armored CAR T therapy for ovarian cancer
GENB•Roswell Park and Generate Biomedicines launched an exclusive clinical trial of GB-5267, an armored CAR T therapy for ovarian cancer designed to avoid pre-infusion chemotherapy. The treatment targets the MUC16 biomarker, found in over 80% of ovarian tumors.
1. Trial targets ovarian cancer
Roswell Park and Generate Biomedicines launched an exclusive clinical trial of GB-5267, an armored CAR T therapy for ovarian cancer. The treatment is designed to avoid pre-infusion chemotherapy and targets MUC16, a biomarker in over 80% of ovarian tumors.
